Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506208 | 0.81 | ADRA2A (0.56) | ADRA2APDE4AADRA1AEPHX1SMN1; SMN2 | |
| SCHEMBL6467646 | 0.80 | EPHX1 (0.42) | ADRA2APDE4AADRA1ATSHREPHX1 | |
| SCHEMBL102987 | 0.78 | LMNA (0.36) | ADRA2APDE4AADRA1AATMRAB9A | |
| SCHEMBL18917213 | 0.78 | TSHR (0.43) | ADRA2APDE4AADRA1ATSHRATM | |
| SCHEMBL2875858 | 0.75 | ATM (0.40) | TSHRATMEPHX1SMN1; SMN2RAB9A | |
| SCHEMBL11209209 | 0.75 | TSHR (0.50) | TSHRATMRAB9AALDH1A1MAPT | |
| SCHEMBL14791027 | 0.75 | LMNA (0.37) | ADRA2APDE4AADRA1ARAB9ANPC1 | |
| SCHEMBL504180 | 0.74 | ALDH1A1 (0.51) | ADRA2APDE4AADRA1ATSHREPHX1 | |
| SCHEMBL965411 | 0.74 | ATM (0.54) | TSHRATMSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9816779 | 0.74 | ATM (0.54) | TSHRATMSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2484 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112618488-B | Self-microemulsion formulations of axitinib | 湖南慧泽生物医药科技有限公司 | 2022-09-23 | — | — | CN | claimed |
| US-11058687-B2 | Human papilloma virus as predictor of cancer prognosis | FOUNDATION MEDICINE, INC. (US) | 2021-07-13 | — | — | US | claimed |
| CN-112618488-A | Self-microemulsion formulations of axitinib | 湖南慧泽生物医药科技有限公司 | 2021-04-09 | — | — | CN | claimed |
| US-10807944-B2 | HDAC inhibitor compounds and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-10-20 | — | — | US | claimed |
| US-20200281930-A1 | HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS | UCL BUSINESS LTD (GB) | 2020-09-10 | — | — | US | claimed |
| US-20200030455-A1 | MULTISTEP TUMOR TARGETING BY TAGGED ANTIBODY DERIVATIVES AND TAGGED DRUGS | UNIVERSITY HOSPITAL JENA (DE) | 2020-01-30 | — | — | US | claimed |
| US-20180338977-A1 | HUMAN PAPILLOMA VIRUS AS PREDICTOR OF CANCER PROGNOSIS | FOUND MEDICINE INC (US) | 2018-11-29 | — | — | US | claimed |
| WO-2018138676-A1 | MULTISTEP TUMOR TARGETING BY TAGGED ANTIBODY DERIVATIVES AND TAGGED DRUGS | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A. (IT) | 2018-08-02 | — | — | WO | claimed |
| US-20180117160-A1 | Method for the Treatment of a Solid Tumour | THE UNIVERSITY OF SYDNEY (AU) | 2018-05-03 | — | — | US | claimed |
| EP-1912658-B1 | THERAPEUTIC PROTOCOLS USING HYALURONAN | ALCHEMIA ONCOLOGY PTY LTD (AU) | 2017-01-25 | — | — | EP | claimed |
| US-20090054537-A1 | THERAPEUTIC PROTOCOLS USING HYALURONAN | ALCHEMIA ONCOLOOGY PTY LIMITED (AU) | 2009-02-26 | — | — | US | claimed |
| EP-1912658-A1 | THERAPEUTIC PROTOCOLS USING HYALURONAN | Alchemia Oncology Pty Limited (AU) | 2008-04-23 | — | — | EP | claimed |
| WO-2007073583-A1 | A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | THE UNIVERSITY OF SYDNEY (AU) | 2007-07-05 | — | — | WO | claimed |
| US-20070066549-A1 | Modulation of elf4e expression | ISIS PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | claimed |
| WO-2007012133-A1 | THERAPEUTIC PROTOCOLS USING HYALURONAN | ALCHEMIA ONCOLOGY PTY LIMITED (AU) | 2007-02-01 | — | — | WO | claimed |
| US-20040072786-A1 | Antisense oligonucleotide inhibition of ras | MONIA BRETT P (US) | 2004-04-15 | — | — | US | claimed |
| US-20030013670-A1 | Antisense oligonucleotide inhibition of ras | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| EP-0668782-B1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | UNIV TEMPLE (US) | 2001-04-11 | — | — | EP | claimed |
| EP-0668782-A1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1995-08-30 | — | — | EP | claimed |
| WO-1994008625-A1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1994-04-28 | — | — | WO | claimed |